

5 August 2011 EMA/CVMP/37837/2011 Veterinary Medicines and Product Data Management

Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents July 2011

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

Scientific advice requests									
	95-08 2009 2010 2011 Total								
Submitted	69	11	21	16	117				
Advice given 65 8 18 13 104									

Initial evaluation										
	95-08 2009 2010 2011 Total									
Full	110	14	16	3	143					
(Submitted)										
Abridged/	10	1	2	1	14					
generics										
(Submitted)										
Withdrawals	12	0	1	0	13					
Positive	91	13	14	14	132					
opinions										
Negative	1	0	0	0	1					
opinions										

Marketing authorisations								
95-08 2009 2010 2011 Total								
Granted	88	12	9	14	123			
Withdrawals	2	0	4	0	6			
Not renewed	2	0	0	0	2			

Extensions								
	95-08	2009	2010	2011	Total			
Submitted	60	12	3	3	77			
Withdrawals	2	1	1	0	4			
Positive	40	7	8	3	58			
opinions								
Negative	0	0	0	0	0			
opinions								



Variations – applications submitted							
	95-08	2009	2010	2011	Total		
Type IA	339	32	76	71	670		
Type IB	337	41	63	48	070		
<u> </u>							
Type II	210	40	26	13	289		
Transfers	11	3	8	3	25		

Renewals							
	95-08	2009	2010	2011	Total		
Submitted	50	18	7	10	85		
Positive	48	17	8	7	80		
opinions							
Negative	0	0	0	0	0		
opinions							

Arbitrations and Community referrals								
	95-08 2009 2010 2011 Total							
Referrals	38	9	12	9	68			
submitted								
Opinions	20	15	11	8	54			
reached ¹		(5)	(1)		(6)			

¹ Re-examination of opinions in brackets

Substances considered as not falling within the scope of Regulation (EC) No 470/2009					
2011 Total					
Submitted	4	4			
Agreed	7	7			
Scientific advice recommended 0 0					

MUMS/ Limited market classification						
	2011	Total				
Positive with financial incentives	6	6				
Positive without financial	9	9				
incentives						
Negative	1	1				

Establishment of MRLs for new substances									
	95-08 2009 2010 2011 Total								
Submitted	66	4	3	1	74				
Withdrawals	5	0	0	0	5				
Positive	54	2	2	3	61				
opinions ²									
Negative	7	0	0	0	7				
opinions ³									

Extensions / modifications/extrapolations of MRLs									
95-08 2009 2010 2011 Total									
Submitted	98	2	10	4	114				
Withdrawals	4	0	0	0	4				
Positive	113	3	3	5	124				
opinions ²									
Negative	6	0	0	0	6				
opinions									
Extrapolations	50	0	0	0	50				

² Including opinions recommending the extension of the expiry date for provisional MRLS or definitive MRLs for substances with previously provisional maximum residue limits
³ Including one opinion concluding that final MRL could not be established for a substance with

provisional maximum residue limits previously established

CVMP opinions in 2011 on medicinal products for veterinary use

Positive opinions

Dro	oduct	•	Marketing	The	erapeutic area	_ L \ /	IA/CVMP	_··	ropean Commission
PIC	ouuct	•	authorisation		•				•
•	Invented name		holder	•	Target species	•	Validation	•	Opinion received
•	INN		Holdel	•	Summary of	•	Opinion	•	Date of decision
					indication	•	Active time	•	Notification
	0 11 1 1					•	Clock stop	•	Official Journal
•	CaniLeish	•	Virbac S.A.	•	Dogs	•	17/03/2010	•	13/01/2011
				•	Vaccine against	•	12/01/2011	•	14/03/2011
					Leishmania infection	•	210	•	17/03/2011
						•	91	•	OJ C 184/15
•	ZULVAC 1 + 8	•	Pfizer Limited	•	Sheep	•	18/03/2010	•	13/01/2011
	Ovis			•	Vaccine for prevention	•	12/01/2011	•	14/03/2011
					of viraemia caused by	•	180	•	17/03/2011
					Bluetongue Virus	•	119	•	OJ C 184/15
					serotypes 1 and 8				
•	BLUEVAC BTV8	•	CZ	•	Cattle, sheep	•	17/01/2009	•	10/02/2011
			Veterinaria	•	Vaccine for active	•	09/02/2011	•	14/04/2011
			S.A		immunisation against	•	210	•	18/04/2011
					bluetongue disease	•	543	•	OJ C 184/15
•	Procox	•	Bayer Animal	•	Dogs	•	16/02/2010	•	11/02/2011
•	Emodepside		Health GmbH	•	Treatment of dogs	•	09/02/2011	•	20/04/2011
	and toltrazuril				when mixed parasitic	•	210	•	28/04/2011
					infections, caused by	•	148	•	OJ C 184/15
					certain specific				
					roundworms and				
					coccidia are suspected				
					or demonstrated				
•	Veraflox	•	Bayer Animal	•	Dogs, cats	•	19/05/2009	•	11/02/2011
•	Pradofloxacin		Health GmbH	•	Treatment for dogs	•	14/07/2010	•	12/04/2011
					and cats with	•	205	•	14/04/2011
					particular infections	•	217	•	OJ C 184/15
					caused by certain		00/02/2011		
					specific and	(==	09/02/2011		
					susceptible pathogens	(re			
<u> </u>	Zuprove		Intonict		Digo pottlo		nsideration)		10/02/2011
•	Zuprevo	•	Intervet	•	Pigs, cattle	•	16/02/2010	•	10/03/2011
•	Tildipirosin		International	•	Treatment of bacterial	•	08/03/2011	•	06/05/2011
			BV		infections in the	•	210		
					respiratory tract in	•	177		
	055715505				pigs and cattle		4 / /00 / 5 5 5 5		40/00/00:
•	CERTIFECT	•	MERIAL SAS	•	Dogs	•	16/03/2010	•	10/03/2011
•	Fipronil, (S)-			•	Treatment and	•	09/03/2011	•	06/05/2011
	methoprene,				prevention of	•	210		
	amitraz				infestations with ticks,	•	148		
					alone or in association				
					with fleas and/or				
					chewing lice				

Dro	duct	•	Marketing	The	erapeutic area	E1/	IA/CVMP	E	ropean Commission
-100	Invented name	•	authorisation	•	Target species	•	Validation	•	Opinion received
	INN		holder	•	Summary of	•	Opinion	•	Date of decision
					indication	•	Active time	•	Notification
						•	Clock stop	•	Official Journal
	MS-H Vaccine	•	Pharmsure	•	Chickens	•	15/12/2009	•	08/04/2011
•	<i>Mycoplasma</i> synoviae strain		Ltd	•	Vaccine to reduce air sac lesions and	•	07/04/2011 206	•	14/06/2011
	MS-H				reduce the number of	•	271		
					eggs with abnormal				
					shell formation				
					caused by				
					Mycoplasma synoviae				
•	Recuvyra	•	Nexcyon	•	Dogs	•	16/12/2009	•	05/05/2011
•	Fentanyl		Pharmaceutic als Ltd	•	Control of post- operative pain	•	04/05/2011 210		
			uis Ltu		associated with major	•	294		
					orthopaedic and soft		-		
					tissue surgery				
	Emdocam	•	Emdoka bvba	•	Cattle, pigs, horses	•	18/05/2010	•	09/06/2011
•	Meloxicam			•	For treatment in	•	09/06/2011		
					respiratory infections,	•	175 211		
					diarrhoea and mastitis in cattle. For	•	211		
					treatment in non-				
					infectious locomotor				
					disorders and in				
					puerperal septicaemia				
					and toxaemia in pigs.				
					In horses for treatment in musculo-				
					skeletal disorders as				
					well for the relief of				
					pain in equine colic.				
•	Proteq West	•	MERIAL	•	Horses	•	18/05/2010	•	09/06/2011
	Nile			•	Vaccine for the active	•	09/06/2011		
	West Nile				immunisation of	•	196		
	recombinant				horses against West	•	190		
	canarypox virus (vCP2017				Nile disease				
	virus)								
	Zulvac 1 Bovis	•	Pfizer Limited	•	Cattle	•	12/08/2010	•	06/07/2011
•	Inactivated			•	Active immunisation	•	09/06/2011		
	Bluetongue				of cattle for the	•	180		
	virus, serotype				prevention of	•	120		
	1, strain BTV-1				viraemia caused by Bluetongue Virus,				
					serotype 1				

Pro	oduct	•	Marketing	The	erapeutic area	EM	IA/CVMP	Eu	ropean Commission
•	Invented name INN		authorisation holder	•	Target species Summary of indication	•	Validation Opinion Active time Clock stop	•	Opinion received Date of decision Notification Official Journal
•	Zulvac 1 Ovis Inactivated Bluetongue Virus, serotype 1, strain BTV-1	•	Pfizer Limited	•	Sheep Active immunisation of sheep for the prevention of viraemia caused by Bluetongue Virus, serotype 1	•	15/07/2010 09/06/2011 179 148	•	06/07/2011
•	Nobivac Myxo- RHD Live myxoma vectored RHD virus strain 009	•	Intervet International BV,	•	Rabbits Active immunisation of rabbits to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease	•	16/02/2010 14/07/2011 210 302	•	15/07/2011
•	Recocam Meloxicam	•	CF Pharma	•	Cattle, pigs, horses For treatment in respiratory infections, diarrhoea and mastitis in cattle. For treatment in non- infectious locomotor disorders and in puerperal septicaemia and toxaemia in pigs. In horses for treatment in musculo- skeletal disorders as well for the relief of pain in equine colic.	•	16/03/2010 14/07/2011 210 274	•	14/07/2011

CVMP opinions in 2011 on establishment of MRLs for new substances

Positive opinions

Substance INN Methylpredni – solone (after provisional MRLs)	Target speciesBovine	EMA/CVMP Validation Opinion Active time Clock stop 12/01/2011 90	European Commission Opinion received Date of regulation Official Journal 27/01/2011
Octenidine dihydrochloride	All mammalian food producing species	11/08/200908/02/2011210246	• 21/02/2011
Monepantel (after provisional MRLs)	Caprine	n/a09/03/2011900	• 25/03/2011
Azamethiphos	Fin fish	 21/02/2011 07/04/2011 45 0 	• 08/04/2011
Pegylated bovine granulocyte colony stimulating factor	Bovine	16/03/201005/05/2011210205	• 18/05/2011
Lasalocid	Bovine	10/08/201005/05/201121058	• 18/05/2011
Ivermectin	All mammalian food producing species	 n/a 09/06/2011 176 0 	• 20/06/2011
Phenoxymethyl- penicillin	Poultry eggs	12/10/201014/07/201121065	• 22/07/2011

Arbitrations and Community referrals in 2011

Type of referral	Date of clock startCVMP opinion	Product nameINN
Referral under Art. 34 of Directive	• 11/11/2009	Fortekor vet and associated names
2001/82/EC		Benazepril hydrochloride
Referral under Art. 34	• 14/04/2010	Synulox Lactating Cow and associated names
of Directive 2001/82/EC	• 07/06/2011	Amoxicillin, clavulanic acid, prednisolone
Referral under Art.	• 14/07/2010	Combimox Lactating Cow
33(4) of Directive 2001/82/EC	• 07/04/2011	Amoxicillin, clavulanic acid, prednisolone
Referral under Art.	• 14/07/2010	Nisamox Lactating Cow
33(4) of Directive 2001/82/EC	• 07/04/2011	Amoxicillin, clavulanic acid, prednisolone
Referral under Art.	• 14/07/2010	Combisyn Lactating Cow
33(4) of Directive 2001/82/EC	• 07/04/2011	Amoxicillin, clavulanic acid, prednisolone
Referral under Art. 34	• 14/07/2010	Doxycycline 50% WSP and associated names
of Directive 2001/82/EC	• 04/05/2011	Doxycycline hyclate
Referral under Art. 34	• 14/07/2010	Doxyfar 50% WSP and associated names
of Directive 2001/82/EC	• 04/05/2011	Doxycycline hyclate
Referral under Art. 34 of Directive	• 09/11/2010	Baytril 10% oral solution and associated names
2001/82/EC		Enrofloxacin
Referral under Art.	• 09/02/2011	Clavudale 50 mg tablet for cats and dogs
33(4) of Directive 2001/82/EC	• 08/06/2011	Amoxicillin and clavulanic acid
Referral under Art. 35 of Directive 2001/82/EC	• 09/03/2011	Veterinary medicinal products containing active substances belonging to the class of flukicides for which no MRL has been established in milk
Referral under Art. 35 of Directive 2001/82/EC	• 06/04/2011	All veterinary medicinal products containing systemically administered (parenteral and oral) 3rd and 4th generation cephalosporins and intended for use in food producing species
		Cefquinome and ceftiofur
Referral under Art. 33(4) of Directive	• 04/05/2011	Prontax 10 mg/ml solution for injection for sheep, cattle and pigs
2001/82/EC		Doramectin

Type of referral	Date of clock startCVMP opinion	Product nameINN
Referral under Art. 33(4) of Directive 2001/82/EC	• 04/05/2011	Prontax 5 mg/ml pour-on solution for cattleDoramectin
Referral under Art. 35 of Directive 2001/82/EC	• 04/05/2011	 All pre-mixes for medicated feedingstuffs containing 40, 100 or 200 g tilmicosin per kg pre-mix Tilmicosin
Referral under Art. 78 of Directive 2001/82/EC	04/05/201114/07/2011	 HIPRABOVIS PNEUMOS Emulsion for injection for cattle and associated names Inactivated Mannheimia haemolytica and Histophilus somni

Guidelines and working documents in 2011

CVMP Efficacy

Reference number	Document title	Status
EMA/CVMP/016/00-Rev.2	Guideline on the conduct of bioequivalence studies for	Adopted April 2011
	veterinary medicinal products	
EMA/CVMP/760764/2010	Concept paper on the revision of	Adopted for consultation,
	the CVMP Guideline for the	April 2011
	demonstration of efficacy for	(End of consultation 21 July
	veterinary medicinal products	(End of consultation 31 July 2011)
	containing antimicrobial substances	2011)
EMA/CVMP/EWP/459868/2008	Guideline on demonstration of	Adopted May 2011
	target animal safety and efficacy of	
	veterinary medicinal products	
	intended for use in farmed finfish	

CVMP Environmental Risk Assessment

Reference number	Document title	Status
EMA/CVMP/ERA/147844/2011	Reflection paper on the testing strategy and risk assessment for plants	Adopted for consultation, March 2011 (End of consultation 30 June 2011)
EMA/CVMP/ERA/430327/2009	Guideline on determining the fate of veterinary medicinal products in manure	Adopted March 2011
EMA/CVMP/ERAWP/409328/2010	Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products	Adopted for consultation, May 2011 (End of consultation 31 August 2011)

Reference number	Document title	Status
EMA/CVMP/ERA/172074/2008-	Questions and answers document	Adopted July 2011
Rev.3	on implementation of ERA Guideline	
	in support of VICH guidelines (GL 6	
	and GL 38)	

CVMP Immunologicals

Reference number	Document title	Status
EMA/CVMP/IWP/206555/2010	Guideline on requirements for the production and control of immunological veterinary medicinal products	Adopted for consultation, March 2011 (End of consultation 30 September 2011)
EMA/CVMP/IWP/314550/2010	Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines	Adopted for consultation, March 2011 (End of consultation 30 September 2011)

CVMP Pharmacovigilance

Reference number	Document title	Status
EMA/CVMP/PhVWP/471721/2006	Recommendation on the basic surveillance of EudraVigilance Veterinary (EVVet) data	Adopted February 2011
EMA/CVMP/PhVWP/44873/2011	Public bulletin - Veterinary pharmacovigilance for 2010	Adopted February 2011
EMA/CVMP/10418/2009-Rev.3	CVMP combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products	Adopted June 2011
EMA/CVMP/PhVWP/377827/2011	List of species and breeds for electronic reporting of suspected adverse reactions in veterinary pharmacovigilance	Adopted June 2011
EMA/CVMP/PhVWP/288284/2007- Rev.4	Quidance notes on the use of VeDDRA terminology for reporting suspected adverse reactions in animals and humans	Adopted June 2011
SOP/V/4019	Standard operating procedure - Annual review of standard lists to be used in EudraVigilance Veterinary	Adopted June 2011

CVMP Scientific Advisory Group on Antimicrobials

Reference number	Document title	Status
EMA/CVMP/SAGAM/736964/2009	Reflection paper on meticillin- resistant <i>Staphylococcus</i> <i>pseudintermedius</i> (MRSP)	Adopted January 2011

General

Reference number	Document title	Status
EMA/347137/2010	Summary of procedures for consultation by CVMP of Scientific Advisory Groups (SAGs) and ad-hoc expert groups functioning as SAGs in relation to applications for authorisation for veterinary medicinal products	Adopted February 2011
EMA/CVMP/287420/2010	CVMP Strategy on antimicrobials 2011-2015	Adopted July 2011
EMA/CVMP/414812/2011	Question and answer document on the CVMP guideline on the SPC for antimicrobial products	Adopted July 2011